Table 1. Tumorigenicity testing by subcutaneous and subretinal transplantation of human iPSC-RPE into NSG mice.
| Cell type | Number of cells transplanted | Number of eyes | Weeks to observe tumor (first to last) | Tumor formation |
|---|---|---|---|---|
| hiPSC | 101 cells | 10 | 15 weeks | None |
| hiPSC | 102 cells | 8 | 15 weeks | None |
| hiPSC | 103 cells | 10 | 15 weeks | None |
| hiPSC | 104 cells | 10 | 15 weeks | 14th week |
| hiPSC | 5×105 cells | 10 | 15 weeks | 8th week |
| hiRPE | 5×105 cells | 10 | 15 weeks | None |
Tumor formation was only detected in NSG mice with 5×105 hiPSCs and 1×104 hiPSCs transplanted. No tumor formation was observed in the iRPE group. All NSG mice were monitored for 15 weeks. hiRPE, human retinal pigmented epithelium derived from induced pluripotent stem cells; hiPSC, human induced pluripotent stem cell.